Infectious PanuveitisNCT04521673
Pathogen Detection in Infectious Uveitis
An observational study of Infectious Panuveitis and Infectious Iridocyclitis, run by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine at 1 site in China.
Trial summary
Infectious uveitis is a very important blinding disease. Some people who have been diagnosed with idiopathic uveitis may also have the activity of pathogens in the eye. However, due to the limitation of the amount of ocular samples, it is difficult to make a rapid and effective diagnosis of infection.Current study is… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Infectious Panuveitis, Infectious Iridocyclitis
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 26 Feb 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patient at a referal hospital eye clinic with clinically suspected infectious uveitis, who undergo AC tap or diagnostic vitrectomy
Who may be able to join
- Patient at a referal hospital eye clinic with clinically suspected infectious uveitis
Who cannot join
- Patients not eligible for the Inclusion Criteria
- Confirmed auto-immune uveitis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xinhua Hospital
Shanghai
Ping Fei, 86-13636342098
Ping Fei, MD，PhD
About this study
Official title: Pathogen Detection in Infectious Uveitis in China
Infectious uveitis is a very important blinding disease. Some people who have been diagnosed with idiopathic uveitis may also have the activity of pathogens in the eye. However, due to the limitation of the amount of ocular samples, it is difficult to make a rapid and effective diagnosis of infection.Current study is to explore the infective cause of uveitis in China by using a broad diagnostic approach of detection.
Read the detailed description
Infectious uveitis is a very important blinding disease. Some people who have been diagnosed with idiopathic uveitis may also have the activity of pathogens in the eye. However, due to the limitation of the amount of ocular samples, it is difficult to make a rapid and effective diagnosis of infection.
The study is to explore the infective cause of uveitis in China by using a broad diagnostic approach of detection, including multiple molecular bio-techniques. We also plan to explore the distribution of pathogens in infectious uveitis.
- Conditions
- Infectious Panuveitis, Infectious Iridocyclitis
- Keywords
- infectious uveitis, pathogen, PCR
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| infectious uveitis | Patients suffering from suspected infectious uveitis, who have vitrectomy performed for diagnostic purpose or anterior chamber tap | |
| Control group | Patients suffering from either cataract surgery or vitrectomy who has been ruled out for infectious ocular diseases |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence and distribution of intraocular infections in the study group
Prevalence and distribution of intraocular infections in the study group
Measured: Oct 2020 to Sep 2022
Secondary outcomes (1)
The sensitivity and specificity of multiple molecular diagnostic methods for detection of bacteria or virus fungi in the study group
The sensitivity and specificity of multiple molecular diagnostic methods for detection of bacteria or virus fungi in the study group
Measured: Oct 2020 to Sep 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2020
- Study start26 Feb 2025
- Primary completion31 Dec 2025
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infectious PanuveitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ping Fei, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Investigators
- Ping Fei, MD，PhD, Principal investigator, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04521673
- Sponsor's protocol ID
- XH-20-014
- Status last verified
- Jul 2026
- First submitted
- 19 Aug 2020
- Last updated
- 30 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pathogen Detection in Infectious Uveitis in China
- ClinicalTrials.gov ID
- NCT04521673
- Acronym / sponsor ID
- XH-20-014
- Conditions
- Infectious Panuveitis, Infectious Iridocyclitis
- Keywords
- infectious uveitis, pathogen, PCR
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of MedicineUniversity, hospital or other
- Study start
- 26 Feb 2025 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 20 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Infectious uveitis is a very important blinding disease. Some people who have been diagnosed with idiopathic uveitis may also have the activity of pathogens in the eye. However, due to the limitation of the amount of ocular samples, it is difficult to make a rapid and effective diagnosis of infection.Current study is to explore the infective cause of uveitis in China by using a broad diagnostic approach of detection.
Detailed description
Infectious uveitis is a very important blinding disease. Some people who have been diagnosed with idiopathic uveitis may also have the activity of pathogens in the eye. However, due to the limitation of the amount of ocular samples, it is difficult to make a rapid and effective diagnosis of infection.
The study is to explore the infective cause of uveitis in China by using a broad diagnostic approach of detection, including multiple molecular bio-techniques. We also plan to explore the distribution of pathogens in infectious uveitis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| infectious uveitis | – | –Patients suffering from suspected infectious uveitis, who have vitrectomy performed for diagnostic purpose or anterior chamber tap |
| Control group | – | –Patients suffering from either cataract surgery or vitrectomy who has been ruled out for infectious ocular diseases |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patient at a referal hospital eye clinic with clinically suspected infectious uveitis, who undergo AC tap or diagnostic vitrectomy
Key inclusion criteria (1 listed)
- Patient at a referal hospital eye clinic with clinically suspected infectious uveitis
Key exclusion criteria (2 listed)
- Patients not eligible for the Inclusion Criteria
- Confirmed auto-immune uveitis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence and distribution of intraocular infections in the study group
Time frame: Oct 2020 to Sep 2022
Prevalence and distribution of intraocular infections in the study group
1 secondary outcome
The sensitivity and specificity of multiple molecular diagnostic methods for detection of bacteria or virus fungi in the study group
Time frame: Oct 2020 to Sep 2022
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
- Individual participant dataSharing planned: Yes
Related trials for Infectious Panuveitis
Not yet recruitingPhase 2
A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)
Noninfectious Intermediate, Posterior, or Panuveitis
Not yet recruitingPhase 2
Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II
Cytomegalovirus (CMV), Anterior Uveitis
Not yet recruitingObservational study
Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant
Noninfectious Posterior Uveitis, Uveitis, Posterior
Active, not recruitingPhase 4
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
Rheumatoid Arthritis, Spondylitis, Ankylosing
RecruitingObservational study
Rheumatology Patient Registry and Biorepository
Rheumatic Diseases, Adult Onset Still Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ping Fei, MD，PhD principal investigator
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infectious Panuveitis and Infectious Iridocyclitis, run by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ping Fei, MD,PhD (86-13636342098, shirleypingfei@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence and distribution of intraocular infections in the study group (time frame: Oct 2020 to Sep 2022). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.